Skip to main content
. Author manuscript; available in PMC: 2020 Sep 19.
Published in final edited form as: Cell Chem Biol. 2019 Jun 27;26(9):1240–1252.e11. doi: 10.1016/j.chembiol.2019.06.003

Figure 1. Foretinib displays non-canonical anticancer activity in NSCLC cells.

Figure 1.

(A) Chemical structures of cabozantinib and foretinib.

(B) Viability-based cellular drug screening after 72 hours of treatment with foretinib (FORE), cabozantinib (CABO), motesanib (MOTE) and PF-04217903 (PF) in a total of 22 NSCLC cells with different genetic background. Displayed above the heatmap are the IC50 or Ki values (in nM) for MET and VEGFR-2 inhibition. Increasing wedges indicate concentrations of 0.5 μM and 2.5 μM. N/A: not applicable.

(C) Dose response curves of FORE, CABO, PF and MOTE for inhibition of viability of H1155 and A427 cells after 72 hours treatment and the respective IC50 values [μM], n = 3, Data are represented as mean ± SD.

(D) Representative clonogenic assay in A427 cells. Cells were treated with the indicated doses of FORE and CABO for 10 days. Data is representative of three independent experiments.